Earnings ·
electroCore reported second quarter 2026 net sales of $9.5 million, a 28% increase from $7.4 million in the prior year…
ECORelectroCore, Inc.
electroCore reported second quarter 2026 net sales of $9.5 million, a 28% increase from $7.4 million in the prior year period. The company posted a GAAP net loss of $3.1 million, down from $3.7 million, with an adjusted EBITDA net loss of $1.8 million, representing a 26% improvement. Revenue growth was driven by U.S. prescription sales to the Department of Veterans Affairs and direct-to-consumer Truvaga channels. The company raised its full-year 2026 revenue guidance to greater than 30% year-over-year growth and expects to achieve positive adjusted EBITDA in the third quarter of 2027. electroCore operates in the bioelectronic medicine industry, developing non-invasive devices for headache treatment and general wellness.